Efficacy of different nitric oxide-based strategies in preventing experimental cerebral malaria by Plasmodium berghei ANKA

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Martins, Yuri C ^a,b   Zanini, Graziela M ^a,c   Frangos, John A ^a   Carvalho, Leonardo J M ^a,d  

^a LA JOLLA BIOENGINEERING INSTITUTE   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; DIPROPYLENETRIAMINE NONOATE; N(G) HYDROXYARGININE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; PHOSPHODIESTERASE V; SILDENAFIL; SODIUM CHLORIDE; SODIUM NITRITE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; BRAIN MALARIA; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; INCIDENCE; MEAN ARTERIAL PRESSURE; MORTALITY; MOUSE; NONHUMAN; OSMOTIC PUMP; PLASMODIUM BERGHEI; PROPHYLAXIS; PULSE PRESSURE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANIMAL; CHEMOPROPHYLAXIS; DRUG COMBINATION; MALARIA; METHODOLOGY; PARASITOLOGY;

MUS; PLASMODIUM BERGHEI;

ANIMALS; ARGININE; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; MALARIA, CEREBRAL; MICE; NITRIC OXIDE; NITRIC OXIDE DONORS; PIPERAZINES; PLASMODIUM BERGHEI; PURINES; SULFONES;

EID: 84856822810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032048     Document Type: Article

References (59)

1. WHO (2010) World Malaria Report Geneva WHO Press.
2. Fernando SD, Rodrigo C, Rajapakse S, (2010) The 'hidden' burden of malaria: cognitive impairment following infection. Malaria journal 9: 366.
3. Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, et al. (2007) Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics 119: e360-366.
4. Boivin MJ, (2002) Effects of early cerebral malaria on cognitive ability in Senegalese children. Journal of developmental and behavioral pediatrics: JDBP 23: 353-364.
5. Dondorp A, Nosten F, Stepniewska K, Day N, White N, (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725.
6. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, et al. (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647-1657.
7. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP, (2010) The murine cerebral malaria phenomenon. Trends in parasitology 26: 11-15.
8. Hunt NH, Grau GE, Engwerda C, Barnum SR, van der Heyde H, et al. (2010) Murine cerebral malaria: the whole story. Trends in parasitology 26: 272-274.
9. Riley EM, Couper KN, Helmby H, Hafalla JC, de Souza JB, et al. (2010) Neuropathogenesis of human and murine malaria. Trends in parasitology 26: 277-278.
10. Renia L, Gruner AC, Snounou G, (2010) Cerebral malaria: in praise of epistemes. Trends in parasitology 26: 275-277.
11. Carvalho LJ, (2010) Murine cerebral malaria: how far from human cerebral malaria? Trends in parasitology 26: 271-272.
12. Stevenson MM, Gros P, Olivier M, Fortin A, Serghides L, (2010) Cerebral malaria: human versus mouse studies. Trends in parasitology 26: 274-275.
13. de Souza JB, Hafalla JC, Riley EM, Couper KN, (2010) Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology 137: 755-772.
14. Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ, (2010) Murine cerebral malaria is associated with a vasospasm-like microcirculatory dysfunction, and survival upon rescue treatment is markedly increased by nimodipine. The American journal of pathology 176: 1306-1315.
15. Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ, (2011) Nitric Oxide Protection Against Murine Cerebral Malaria Is Associated With Improved Cerebral Microcirculatory Physiology. The Journal of infectious diseases.
16. Gramaglia I, Sobolewski P, Meays D, Contreras R, Nolan JP, et al. (2006) Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nature medicine 12: 1417-1422.
17. Pluta RM, (2011) New regulatory, signaling pathways, and sources of nitric oxide. Acta neurochirurgica Supplement 110: 7-12.
18. Weitzberg E, Hezel M, Lundberg JO, (2010) Nitrate-nitrite-nitric oxide pathway: implications for anesthesiology and intensive care. Anesthesiology 113: 1460-1475.
19. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, et al. (2007) Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. The Journal of experimental medicine 204: 2693-2704.
20. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, et al. (1996) Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. The Journal of experimental medicine 184: 557-567.
21. Lopansri BK, Anstey NM, Weinberg JB, Stoddard GJ, Hobbs MR, et al. (2003) Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet 361: 676-678.
22. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, et al. (2010) Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS pathogens 6: e1000868.
23. Morris SM Jr, (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. British journal of pharmacology 157: 922-930.
24. Weinberg JB, Lopansri BK, Mwaikambo E, Granger DL, (2008) Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. Current opinion in infectious diseases 21: 468-475.
25. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, et al. (2008) Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. The Journal of infectious diseases 198: 602-608.
26. Libonati RM, Cunha MG, Souza JM, Santos MV, Oliveira SG, et al. (2006) Estradiol, but not dehydroepiandrosterone, decreases parasitemia and increases the incidence of cerebral malaria and the mortality in plasmodium berghei ANKA-infected CBA mice. Neuroimmunomodulation 13: 28-35.
27. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, et al. (2008) Safety profile of L-arginine infusion in moderately severe falciparum malaria. PloS one 3: e2347.
28. Crabtree MJ, Channon KM, (2011) Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric oxide: biology and chemistry/official journal of the Nitric Oxide Society.
29. Corbin JD, Francis SH, (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. The Journal of biological chemistry 274: 13729-13732.
30. Rodrigo R, Monfort P, Cauli O, Erceg S, Felipo V, (2006) Pharmacological manipulation of cyclic GMP levels in brain restores learning ability in animal models of hepatic encephalopathy: therapeutic implications. Neuropsychiatric disease and treatment 2: 53-63.
31. Doyle MP, Hoekstra JW, (1981) Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. Journal of inorganic biochemistry 14: 351-358.
32. Pluta RM, Dejam A, Grimes G, Gladwin MT, Oldfield EH, (2005) Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA: the journal of the American Medical Association 293: 1477-1484.
33. Gladwin MT, Kim-Shapiro DB, (2008) The functional nitrite reductase activity of the heme-globins. Blood 112: 2636-2647.
34. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, et al. (2003) Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature medicine 9: 1498-1505.
35. Clemmer L, Martins YC, Zanini GM, Frangos JA, Carvalho LJ, (2011) Artemether and artesunate show the highest efficacy to rescue mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain. Antimicrob Agents Chemother 4: 1383-1390.
36. Martins YC, Werneck GL, Carvalho LJ, Silva BP, Andrade BG, et al. Algorithms to predict cerebral malaria in murine models using the SHIRPA protocol. Malar J 9: 85.
37. Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, et al. (2006) Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol 32: 177-188.
38. Campistron G, Guiraud R, Cros J, Mosser J, (1982) Pharmacokinetics of arginine and aspartic acid administered simultaneously in the rat: I. Plasma kinetics. European journal of drug metabolism and pharmacokinetics 7: 307-313.
39. Campistron G, Guiraud R, Cros J, Prat G, (1982) Pharmacokinetics of arginine and aspartic acid administered simultaneously in the rat: II. Tissue distribution. European journal of drug metabolism and pharmacokinetics 7: 315-322.
40. Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, et al. (2007) Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arteriosclerosis, thrombosis, and vascular biology 27: 865-870.
41. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, et al. (2000) Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circulation research 87: 566-573.
42. Kure S, Sato K, Fujii K, Aoki Y, Suzuki Y, et al. (2004) Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Molecular genetics and metabolism 83: 150-156.
43. Verhaar MC, Westerweel PE, van Zonneveld AJ, Rabelink TJ, (2004) Free radical production by dysfunctional eNOS. Heart 90: 494-495.
44. Bratt JM, Franzi LM, Linderholm AL, O'Roark EM, Kenyon NJ, et al. (2010) Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicology and applied pharmacology 242: 1-8.
45. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, et al. (2002) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke; a journal of cerebral circulation 33: 2675-2680.
46. Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, et al. (2005) Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke; a journal of cerebral circulation 36: 847-852.
47. Astrand A, Bohlooly YM, Larsdotter S, Mahlapuu M, Andersen H, et al. (2004) Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity. Am J Physiol Regul Integr Comp Physiol 287: R749-758.
48. Luiking YC, Engelen MP, Deutz NE, (2010) Regulation of nitric oxide production in health and disease. Current opinion in clinical nutrition and metabolic care 13: 97-104.
49. Curfs JH, Schetters TP, Hermsen CC, Jerusalem CR, van Zon AA, et al. (1989) Immunological aspects of cerebral lesions in murine malaria. Clinical and experimental immunology 75: 136-140.
50. Yeo TW, Rooslamiati I, Gitawati R, Tjitra E, Lampah DA, et al. (2008) Pharmacokinetics of L-arginine in adults with moderately severe malaria. Antimicrobial agents and chemotherapy 52: 4381-4387.
51. Kharitonov S, Alving K, Barnes PJ, (1997) Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 10: 1683-1693.
52. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Kenangalem E, et al. (2009) Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. The Journal of infectious diseases 200: 1522-1529.
53. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature medicine 8: 1383-1389.
54. Halaris A, Plietz J, (2007) Agmatine: metabolic pathway and spectrum of activity in brain. CNS drugs 21: 885-900.
55. Morris SM Jr, (2007) Arginine metabolism: boundaries of our knowledge. The Journal of nutrition 137: 1602S-1609S.
56. Mun CH, Lee WT, Park KA, Lee JE, (2010) Regulation of endothelial nitric oxide synthase by agmatine after transient global cerebral ischemia in rat brain. Anatomy & cell biology 43: 230-240.
57. Vallance P, Leone A, Calver A, Collier J, Moncada S, (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. Journal of cardiovascular pharmacology 20 (Suppl 12): S60-62.
58. Davis JS, Darcy CJ, Yeo TW, Jones C, McNeil YR, et al. (2011) Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. PloS one 6: e17260.
59. Lue TF, (2000) Erectile dysfunction. The New England journal of medicine 342: 1802-1813.